AbCellera Biologics : Q1 2024 Business Update

C OP YRIG HT © AB C E LLE RA

Q1 2024

BUSINESS UPDATE

MAY 7, 2024

DISCLAIMER

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

2

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward- looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

3

2 0 2 4 P R I O R I T I E S

As we move programs toward the

clinic, we are prioritizing:

1						2		3
Internal		Engine &		Strategic
Programs &
	Capabilities		Partnerships
Pipeline

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

4

O U R E N G I N E . P L A T F O R M D E V E L O P M E N T

New data demonstrates highly differentiated T-cell engager platform.

Presented at AACR 2024

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

5

O U R E N G I N E . P L A T F O R M D E V E L O P M E N T

Widening the therapeutic window across solid tumor indications.

We describe the generation of T-cell engagers for three solid tumor targets, PSMA, B7-H4, and 5T4, with functional

profiles that are differentiated from clinical benchmarks.

These molecules were engineered using a specific set of rare CD3-bindingantibodies that consistently show potent tumor-cellkilling and low cytokine release across multiple targets, demonstrating their potential to expand the therapeutic window across solid tumor indications.

Potent molecules with functional profiles that rival clinical benchmarks

Log [bispecific] (nM)

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

6

O U R E N G I N E . P L A T F O R M D E V E L O P M E N T

We are using our T-cell engager platform as a source of internal programs and

a basis for strategic partnerships.

Our focus is to test in vivo and

to advance a subset of programs.

Our TCE platform is nearly complete.

In addition to having highly differentiated proprietary CD3s, we have also developed panels of antibodies that can be used to enhance T-cell activation, survival via signal-2 costimulation, and have demonstrated the ability to target MHC peptides.

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

7

O U R P A R T N E R S

We advanced strategic partnerships with established biopharmas and top-tierinvestment groups.

ESTABLISHED	1 Program	NEUROLOGY
BIOPHARMA

COMPANY CREATION	Multiple Programs	IMMUNOLOGY
with Investment Groups

C O P Y R I G H T © A B C E L L E R A

Q1 2024 FINANCIALS UPDATE

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

9

Continued progress on key business metrics and a strong cash position.

~$1B $725M 90 13 2

In available liquidity to execute on our strategy

in total cash,

cash equivalents, & marketable securities

cumulative partner- initiated program starts with downstreams

molecules in the clinic

internal programs advanced into IND-enabling studies

FINANCIALS

Q1 2024 BUSINESS UPDATE

COPYRIGHT © ABCELLERA

10

Continuing portfolio growth.

Cumulative # of

PARTNER-INITIATED PROGRAM STARTS

WITH DOWNSTREAMS

90										90
80
70
60
50
40
30
20
10
0
2015	16	17	18	19	20	21	22	23	24
											Q1

Cumulative # of

MOLECULES IN THE CLINIC

13										13
12
11
10
9
8
7
6
5
4
3
2
1
0
2015	16	17	18	19	20	21	22	23	24
											Q1